Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Exenatide · Byetta, AC-002993

Peptide · Agonist of Glucagon-like peptide-1 receptor (GLP1R) · developed by Astrazeneca

Approved FDA, Apr 2005
1 Registered trials

What is Exenatide?

Exenatide is a peptide that partly overlaps the sequence of human GLP-1 and binds and activates the GLP-1 receptor. It enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon secretion and slows gastric emptying. It is studied in type 2 diabetes mellitus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Byetta, AC-002993, AC-2993, AC-2993A
Drug type
Peptide
Targets
Glucagon-like peptide-1 receptor (GLP1R)
Mechanism
Agonist of Glucagon-like peptide-1 receptor (GLP1R)
Pathways
cyclic AMP signaling, glucose-dependent insulin secretion, glucagon suppression, gastric emptying
Therapy area
Endocrine, Metabolic
Developer
Astrazeneca Ab
In trials of
OPK
FDA status
Approved as Byetta (April 28, 2005), NDA021773 · FDA label
UNII
9P1872D4OL

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 2, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02119819 Phase 2 Diabetes Mellitus, Type 2 Completed OPK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes Mellitus, Type 2

Other drugs acting on GLP1R

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.